Relmada Therapeutics Inc (RLMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has a cash flow conversion efficiency ratio of -0.069x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.07 Million) by net assets ($218.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Relmada Therapeutics Inc (RLMD) market capitalisation for the company's overall valuation and market capitalisation.
Relmada Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Relmada Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Relmada Therapeutics Inc ranked by their cash flow conversion efficiency. Explore RLMD cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu KSW Technologies Co. Ltd. A
SHG:688283
|
0.039x |
|
Global Dominion Access S.A
MC:DOM
|
0.211x |
|
DOUBLED.INTERAC.SP.ADS/20
F:DDI
|
0.045x |
|
Poly Union Chemical Holding Group Co Ltd
SHE:002037
|
0.023x |
|
Natural Gas Services Group Inc
NYSE:NGS
|
0.082x |
|
Zhejiang Jiaxin Silk Corp Ltd
SHE:002404
|
-0.073x |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
N/A |
|
Citizens & Northern Corp
NASDAQ:CZNC
|
0.045x |
Annual Cash Flow Conversion Efficiency for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Relmada Therapeutics Inc from 2012 to 2025. View RLMD stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $86.51 Million | $-45.79 Million | -0.529x | +63.68% |
| 2024-12-31 | $35.52 Million | $-51.76 Million | -1.457x | -140.74% |
| 2023-12-31 | $85.36 Million | $-51.66 Million | -0.605x | +18.12% |
| 2022-12-31 | $140.44 Million | $-103.80 Million | -0.739x | -67.55% |
| 2021-12-31 | $208.26 Million | $-91.87 Million | -0.441x | -67.49% |
| 2020-12-31 | $105.58 Million | $-27.81 Million | -0.263x | -251866.34% |
| 2019-12-31 | $115.68 Million | $-12.09K | 0.000x | -100.01% |
| 2018-12-31 | $-5.51 Million | $-6.00 Million | 1.089x | +124.59% |
| 2017-12-31 | $1.46 Million | $-6.47 Million | -4.428x | -137.26% |
| 2016-12-31 | $7.04 Million | $-13.14 Million | -1.866x | -1.33% |
| 2015-12-31 | $8.81 Million | $-16.23 Million | -1.842x | 0.00% |
| 2014-12-31 | $8.81 Million | $-16.23 Million | -1.842x | -191.19% |
| 2014-06-30 | $-1.11 Million | $-2.24 Million | 2.020x | +18788.61% |
| 2013-12-31 | $-1.11 Million | $-11.86K | 0.011x | +101.61% |
| 2012-12-31 | $11.36K | $-7.57K | -0.666x | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more